Canada markets open in 5 hours 29 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
13.98-0.07 (-0.50%)
At close: 04:00PM EDT
14.01 +0.03 (+0.21%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close14.05
Open13.98
Bid0.00 x 2200
Ask0.00 x 3200
Day's Range13.70 - 14.14
52 Week Range7.09 - 14.47
Volume9,492,102
Avg. Volume9,279,165
Market Cap15.834B
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target EstN/A
  • GuruFocus.com

    Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...

    Corcept reports a robust financial performance and advances in clinical trials, despite facing potential generic competition.

  • Reuters

    UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

    The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.

  • Reuters

    U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

    WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.